Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;23(12):841-848.
doi: 10.1007/s11910-023-01316-9. Epub 2023 Nov 9.

Recent Advances in Pediatric Medulloblastoma

Kasey Jackson  1   2 , Roger J Packer  3   4
Affiliations
Review

Recent Advances in Pediatric Medulloblastoma

Kasey Jackson et al. Curr Neurol Neurosci Rep. 2023 Dec.

Abstract

Purpose of review: Review recent advances in the understanding of pediatric medulloblastoma including etiology, biology, radiology, and management of pediatric medulloblastoma.

Recent findings: The classic four subgroups have been reclassified and further subdivided based on new molecular findings. Research is revealing the cell origins of the different subtypes of medulloblastoma. There has been continued personalization of management based on molecular parameters. While many advances have been made in the knowledge base of this most common malignant pediatric brain tumor, there has not yet been translation into more effective therapies to prolong survival in all subgroups with the possible exception of children with group 3 disease. Quality of life remains a major challenge for long-term survivors.

Keywords: Brain tumors; Chemotherapy; Pediatric medulloblastoma; Radiation therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Ostrom QT, Price M, Ryan K, Edelson J, Neff C, Cioffi G, et al. CBTRUS statistical report: pediatric Brain Tumor Foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro-Oncol. 2022;24(Supplement 3):iii1–iii38. doi: 10.1093/neuonc/noac161. - DOI - PMC - PubMed
    1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
    1. Wang J, Garancher A, Ramaswamy V, Wechsler-Reya RJ. Medulloblastoma: from molecular subgroups to molecular targeted therapies. Annu Rev Neurosci. 2018;41:207–232. doi: 10.1146/annurev-neuro-070815-013838. - DOI - PubMed
    1. Zhang M, Wong SW, Wright JN, Wagner MW, Toescu S, et al. MRI radiogenomics of pediatric medulloblastoma: A multicenter study. Radiol. 2022;304:406–416. doi: 10.1148/radiol.212137. - DOI - PMC - PubMed
    1. Begemann M, Waszak SM, Robinson GW, Jäger N, Sharma T, et al. Germline GPR161 mutations predispose to pediatric medulloblastoma. J Clin Oncol. 2020;38(1):43–50. doi: 10.1200/JCO.19.00577. - DOI - PMC - PubMed